Sarah Weckhuysen (Belgium)
University Hospital Antwerp - VIB UAntwerp Neurology Department - Center for Molecular NeurologyAuthor Of 2 Presentations
WHEN SHOULD WE REQUEST A GENETIC TEST IN CHILDHOOD EPILEPSIES, AND WHICH TEST?
- Sarah Weckhuysen (Belgium)
GENETICS TRANSFORMING EPILEPSY CARE
- Sarah Weckhuysen (Belgium)
Abstract
Abstract Body
The last decade has seen an increased use and yield of genetic testing in a broad spectrum of epilepsies, especially in the group of the developmental and epileptic encephalopathies. Also adults with epilepsy are now increasingly considered for genetic testing, especially if there is an association with cortical malformations or neurodevelopmental problems. Whereas initial clinical benefits mainly were based on improved counseling about prognosis and recurrence risk, for several genetic epilepsies research discoveries are now being translated into novel treatment strategies including strategies for gene regulation, gene therapy, and anti-seizure medications that obtained orphan drug designations. This presentation will give an overview of how recent developments in genetics have changed our care for (a subset of) epilepsy patients.
Presenter of 2 Presentations
WHEN SHOULD WE REQUEST A GENETIC TEST IN CHILDHOOD EPILEPSIES, AND WHICH TEST?
- Sarah Weckhuysen (Belgium)
GENETICS TRANSFORMING EPILEPSY CARE
- Sarah Weckhuysen (Belgium)
Abstract
Abstract Body
The last decade has seen an increased use and yield of genetic testing in a broad spectrum of epilepsies, especially in the group of the developmental and epileptic encephalopathies. Also adults with epilepsy are now increasingly considered for genetic testing, especially if there is an association with cortical malformations or neurodevelopmental problems. Whereas initial clinical benefits mainly were based on improved counseling about prognosis and recurrence risk, for several genetic epilepsies research discoveries are now being translated into novel treatment strategies including strategies for gene regulation, gene therapy, and anti-seizure medications that obtained orphan drug designations. This presentation will give an overview of how recent developments in genetics have changed our care for (a subset of) epilepsy patients.
Moderator of 1 Session
- Sarah Weckhuysen (Belgium)